Concepedia

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

Christian Monnerat, Roger Henriksson, Thierry Le Chevalier, Silvia Novello, P. Berthaud, Sandrine Faivre, Éric Raymond

Annals of Oncology · 2004 · 66 citations · 21 references

DOIFull text

Open access

Concepts

References

21

Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer

John O’Quigley, Margaret S. Pepe, Lloyd D. Fisher · Biometrics · 1990 · 1.6K citations

, , +14

Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

Richard J. Gralla, David Osoba, Mark G. Kris et al. · Journal of Clinical Oncology · 1999 · 670 citations

, , +15

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

Stephanie Green, Geoffrey R. Weiss · Investigational New Drugs · 1992 · 616 citations

, , +14

Halting angiogenesis suppresses carcinoma cell invasion

Mihaela Skobe, Patricia Rockwell, Neil I. Goldstein et al. · Nature Medicine · 1997 · 427 citations

, , +14

A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and <i>In vitro</i> anti‐proliferative as well as <i>In vivo</i> anti‐tumor activity

Thomas Meyer, Urs Regenass, Doriano Fabbro et al. · International Journal of Cancer · 1989 · 408 citations

, , +13